Cellectis, a clinical-stage biotech company specializing in gene-editing therapies, announced it will report its financial results for the first quarter of 2026 on May 11, after the US market closes. The company, known for its allogeneic CAR T-cell therapies for cancer and gene therapy platforms, will publish the results on its website but will not hold a conference call. Investors can direct questions to the company's investor relations team. This update is important as it provides insight into the company's financial health and progress in its pioneering gene-editing treatments.
Asset Workflows Ltd, a UK-based asset data management firm, received a major strategic investment led by CoMade and two healthcare investors. This funding will accelerate its expansion in Australia and the Asia-Pacific region, enhance product develop...
Talk of a Tesla-SpaceX merger is intensifying as Elon Musk moves closer to taking SpaceX public. The two companies already share engineering talent and collaborate on energy, computing, and infrastructure challenges. The potential deal is largely dri...
TIFIN.AI has launched TIFIN Australia, a new joint venture aimed at bringing advanced AI technology to the Australian wealth management market. Led by experienced executives Marcus Price and Justin Schmitt, the platform will offer AI-native solutions...
Agora, Inc. announced its Q1 2026 financial results with revenues rising 13.5% to $37.7 million and net income increasing to $1.1 million, marking its sixth consecutive quarter of GAAP profitability. The company launched Agent Studio, a no-code platf...
Webco Industries reported a net income of $8.0 million for Q3 fiscal 2026, up from $5.0 million the previous year, driven by a 15.6% increase in net sales to $179.6 million. The company also saw improved gross profit margins and increased operating i...
